LAMA

This page shows the latest LAMA news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol, LAMA

Latest news

EMA approves GSK’s triple COPD therapy

The same indication was approved by the FDA in September, and makes Trelegy the first drug on the market to combine an ICS, LABA and long-acting muscarinic receptor antagonist (LAMA)
With US approval, GSK now needs rapid uptake for COPD triple

The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product
GSK closes in on EU approval for triple COPD therapy

The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... GSK thinks it has a decent head
GSK preps COPD filing for asthma pioneer Nucala

agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium – and shingles vaccine Shingrix which is up for an FDA advisory committee meeting later today.
Chiesi Group's Trimbow wins European licence

The treatment comprises an inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in one inhaler and is the such triple combination COPD therapy to be ... Administered twice daily at a fixed dose,

More from news
Approximately 3 fully matching, plus 48 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.
Pharma deals in February 2015

The co-development and marketing deal with Theravance involves TD-4208 a novel, phase 3 ready, once-daily, nebulised, long-acting muscarinic antagonist (LAMA) under development to treat COPD and other
Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

Currently in phase III clinical development for COPD, this combination of a long acting beta-2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Editor – Medical Education Agency – Bucks: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager / Account Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Programme Executive: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Medical Writer, e-learning/ training, London: Excellent Salary

Project Manager, Medical Communications, London: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...